Update and optimization of active surveillance in prostate cancer in 2021

Within the paradigm shift of the last decade in the management of prostate cancer (PCa), perhaps the most relevant event has been the emergence of active surveillance (AS) as a mandatory strategy in low-risk disease. We carry out a critical review of the clinical, pathological and radiological improvements that allow optimizing AS in 2021. Critical narrative review of the literature on improvement issues and controversial aspects of AS. Adequate...